Experimental 'Alarm' therapy aims to rev up immune system against Hard-to-Treat cancers
NCT ID NCT05338658
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new approach called Peptide Alarm Therapy (PAT) for people with advanced solid tumors that have not responded to at least one prior treatment, including immunotherapy. PAT is injected directly into a tumor along with a standard PD-1 inhibitor drug. The goal is to see if this combination is safe and can help shrink or control the cancer. Only 21 participants who have certain immune markers (CMV and EBV positive, and a specific HLA type) will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Peptide Alarm Therapy (PAT) combined with pembrolizumab (a PD-1 inhibitor)
What this could lead to
If it works, this could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase I trial with only 21 participants, so it is too soon to know if it will be safe or effective. The treatment is given directly into tumors and may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Masonic Cancer Center at University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact